Experimental study demonstrates significant tumor growth inhibition in rats with DMBA-induced carcinoma, suggesting potential therapeutic effects of uncaria gambir.
Objective: To investigate the antitumor effects of U. gambir extract on 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary carcinoma in Wistar rats. Methodology: This experimental study included 30 female rats divided in five groups receiving different U. gambir extracts at 200mg/kg, 600mg/kg, 1000mg/kg body weight (BW), and positive control (capecitabine 65mg/kg BW). Apoptosis, inflammation, and angiogenesis induction were assessed by immunohistochemistry, and quantifying biomarkers caspase-3, NF-KB, and VEGFR-2 expressions using the Histoscore method. Statistical analyses included one-way ANOVA (tumor volume) with Bonferroni posthoc and chi-square tests for biomarker expression. Results: The 600 mg/kg BW U. gambir group exhibited significant tumor growth inhibition (p<0.01). A trend toward increased caspase-3 and NF-KB expression was observed in the 600 mg/kg group and 200mg/kg group respectively, although it did not achieve statistical significance (p>0.05). VEGFR-2 expression is no different compared to the control group. Conclusions: These findings suggest that U. gambir extracts have antitumor activity by decreasing tumor volume. However, further research is essential to define the mechanistic pathways and identify active components.
No takes yet. Share an insight, caveat, or question.
Prabudi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: